$2.47 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 109 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 53.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | Buy | HORIZON PHARMA PLC | $253,210,000 | +58.1% | 11,684,801 | +44.6% | 10.26% | +65.6% |
| ADPTQ | Buy | ADEPTUS HEALTH INCcl a | $71,307,000 | +61.9% | 1,307,908 | +139.8% | 2.89% | +69.6% |
| DVA | Buy | DAVITA HEALTHCARE PARTNERS I | $57,302,000 | +10.6% | 822,000 | +14.8% | 2.32% | +15.9% |
| VNDA | Buy | VANDA PHARMACEUTICALS INC | $55,829,000 | +3.5% | 5,996,691 | +25.3% | 2.26% | +8.4% |
| GILD | New | GILEAD SCIENCES INCcall | $53,833,000 | – | 532,000 | +100.0% | 2.18% | – |
| TEVA | Buy | TEVA PHARMACEUTICAL INDS LTDadr | $53,497,000 | +54.1% | 815,000 | +32.5% | 2.17% | +61.4% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $37,626,000 | +0.2% | 1,163,811 | +30.7% | 1.52% | +5.0% |
| PTLA | Buy | PORTOLA PHARMACEUTICALS INC | $35,179,000 | +150.2% | 683,749 | +107.3% | 1.43% | +162.1% |
| XNPT | Buy | XENOPORT INC | $34,518,000 | +188.7% | 6,287,374 | +82.5% | 1.40% | +202.8% |
| AACH | Buy | AAC HLDGS INC | $33,967,000 | -4.7% | 1,782,094 | +11.3% | 1.38% | -0.1% |
| INFI | Buy | INFINITY PHARMACEUTICALS INC | $33,797,000 | +2.3% | 4,305,288 | +10.1% | 1.37% | +7.2% |
| New | ENDOLOGIX INCnote 3.250%11/0 | $32,548,000 | – | 30,000,000 | +100.0% | 1.32% | – | |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $28,220,000 | – | 680,000 | +100.0% | 1.14% | – |
| DNAI | Buy | PRONAI THERAPEUTICS INC | $26,940,000 | -2.6% | 1,791,255 | +32.8% | 1.09% | +2.1% |
| CTMX | New | CYTOMX THERAPEUTICS INC | $19,743,000 | – | 946,022 | +100.0% | 0.80% | – |
| CNC | New | CENTENE CORP DEL | $16,058,000 | – | 244,000 | +100.0% | 0.65% | – |
| CSII | New | CARDIOVASCULAR SYS INC DEL | $15,649,000 | – | 1,035,000 | +100.0% | 0.63% | – |
| GI | Buy | ENDOCHOICE HLDGS INC | $15,225,000 | -25.4% | 1,823,309 | +1.4% | 0.62% | -21.9% |
| ALIM | Buy | ALIMERA SCIENCES INC | $14,225,000 | +45.6% | 5,878,015 | +33.0% | 0.58% | +52.6% |
| IMPR | Buy | IMPRIVATA INC | $13,633,000 | -33.4% | 1,206,418 | +4.8% | 0.55% | -30.1% |
| XLRN | New | ACCELERON PHARMA INC | $10,410,000 | – | 213,491 | +100.0% | 0.42% | – |
| IVTY | Buy | INVUITY INC | $9,510,000 | +237.4% | 1,078,218 | +436.2% | 0.38% | +253.2% |
| HTWR | Buy | HEARTWARE INTL INC | $8,062,000 | +14.8% | 159,961 | +19.2% | 0.33% | +20.2% |
| ADHD | Buy | ALCOBRA LTD | $6,719,000 | +11.5% | 1,069,914 | +7.3% | 0.27% | +16.7% |
| VSAR | Buy | VERSARTIS INC | $6,077,000 | +90.3% | 490,503 | +77.1% | 0.25% | +98.4% |
| PSDV | Buy | PSIVIDA CORP | $5,891,000 | +66.0% | 1,222,110 | +25.7% | 0.24% | +74.5% |
| MYOK | New | MYOKARDIA INC | $5,498,000 | – | 375,000 | +100.0% | 0.22% | – |
| ZFGN | Buy | ZAFGEN INC | $5,307,000 | -70.0% | 843,665 | +52.4% | 0.22% | -68.6% |
| VYGR | New | VOYAGER THERAPEUTICS INC | $5,153,000 | – | 235,294 | +100.0% | 0.21% | – |
| CATB | Buy | CATABASIS PHARMACEUTICALS IN | $5,104,000 | +0.4% | 643,580 | +2.4% | 0.21% | +5.1% |
| GNCA | Buy | GENOCEA BIOSCIENCES INC | $4,412,000 | +28.5% | 837,257 | +67.0% | 0.18% | +34.6% |
| STDY | Buy | STEADYMED LTD | $4,390,000 | -6.0% | 1,346,744 | +2.4% | 0.18% | -1.7% |
| SCYX | Buy | SCYNEXIS INC | $4,324,000 | -14.3% | 696,281 | +0.5% | 0.18% | -10.3% |
| ALQA | Buy | ALLIQUA BIOMEDICAL INC | $4,023,000 | -24.4% | 1,880,134 | +12.1% | 0.16% | -20.9% |
| IMMU | New | IMMUNOMEDICS INC | $3,296,000 | – | 1,073,640 | +100.0% | 0.13% | – |
| VCYT | Buy | VERACYTE INC | $2,823,000 | +57.1% | 392,147 | +2.3% | 0.11% | +62.9% |
| CTIC | New | CTI BIOPHARMA CORP | $2,751,000 | – | 2,236,832 | +100.0% | 0.11% | – |
| RNVA | New | RENNOVA HEALTH INC | $755,000 | – | 559,431 | +100.0% | 0.03% | – |
| ABC | New | AMERISOURCEBERGEN CORP | $311,000 | – | 3,000 | +100.0% | 0.01% | – |
| New | RENNOVA HEALTH INC*w exp 12/22/202 | $285,000 | – | 645,161 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-14 |
| 4 | 2024-06-03 |
| 13F-HR | 2024-05-15 |
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.